Back to search results

Explore carbon emissions data for Recipharm AB. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.

This profile brings together available carbon emissions data for Recipharm AB, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. It is one entry in the Mycelium emissions database. Read how we source and check this data.

Emissions

Carbon emissions

Total yearly emissions across all scopes

206,764tCO2e(Market Based)(Mycelium adjusted)

Reported by Recipharm AB
196,109 tCO₂e
Estimated by Mycelium
10,655 tCO₂e

Recipharm AB reported 95% of the adjusted total. Mycelium estimated the remaining 5% for the categories it did not disclose. Recipharm AB reported 45,330 tCO₂e of Scope 3 emissions beyond its breakdown into categories. The model of the categories it did not report comes to more than that, so the adjusted total counts the model, with the reported figure inside it.

Scope 1

tCO2e

20,956

Scope 2 (Market Based)

tCO2e

805

Scope 3 total

tCO2e

185,003

Figures from page 17 of the source report

Scope 3 reported

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

Something wrong? Contribute to this dataset

See the scope breakdown

Provenance

Review the sources and documents behind Recipharm AB's emissions data. Provenance matters because it shows where the information comes from, how recent it is and how complete the disclosure appears to be.

Documents

Emissions
Factors

Modelled emission factorScope 1, 2 and upstream Scope 3 (categories 1–8)
0.196kgCO2e / $

Sustainability
Snapshot

Based on reported data, retrieved with AI

  • Recipharm AB reported 196,109 tCO₂e in 2025.
  • Scope 3 accounted for 89% of reported emissions.
  • Reported across 2 of 15 GHG Protocol Scope 3 categories.
  • Scope 2 reported under the market based methodology.

According to available emissions disclosures, Recipharm AB reported total yearly emissions of 196,109 tCO₂e in 2025. Scope 3 emissions accounted for 89% of the reported footprint, indicating supply chain activity, purchased goods and services, business travel, and wider operational dependencies were the most significant contributors to the company's carbon footprint.

The company achieved a Mycelium Score of 4.9, placing it mid-pack within its sector for sustainability performance, and received a transparency score of 79.2, meaning they share solid detail across the main emissions areas.

Scope
breakdown

Scope 1 emissions

Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.

REPORTED

Direct emissions

20,956

tCO2e

Scope 2 emissions

Indirect emissions from purchased energy, including electricity, heating and cooling.

Location based

–

tCO2e
REPORTED

Market based

805

tCO2e

Scope 3 emissions

Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.

Recipharm AB reported 45,330 tCO₂e of Scope 3 emissions beyond its breakdown into categories. Mycelium's model of the categories it did not report comes to more than that, so the estimates below replace it in the adjusted total, with the reported figure counted inside them. The reported figure is not discarded, and you can see it in the downloads below.

REPORTED

Cat 1

Purchased goods & services

127,274

tCO2e
ESTIMATED

Cat 2

Capital goods

6,506

tCO2e
ESTIMATED

Cat 3

Fuel & energy related activities

14,015

tCO2e
ESTIMATED

Cat 4

Upstream transportation & distribution

5,355

tCO2e
ESTIMATED

Cat 5

Waste generated in operations

1,104

tCO2e
ESTIMATED

Cat 6

Business travel

4,874

tCO2e
ESTIMATED

Cat 7

Employee commuting

3,806

tCO2e
ESTIMATED

Cat 8

Upstream leased assets

330

tCO2e
ESTIMATED

Cat 9

Downstream transportation & distribution

1,552

tCO2e
ESTIMATED

Cat 10

Processing of sold products

4,591

tCO2e
ESTIMATED

Cat 11

Use of sold products

6,005

tCO2e
REPORTED

Cat 12

End-of-life treatment of sold products

1,743

tCO2e
ESTIMATED

Cat 13

Downstream leased assets

361

tCO2e
ESTIMATED

Cat 14

Franchises

6,673

tCO2e
ESTIMATED

Cat 15

Investments

813

tCO2e

13 values were derived via Mycelium's normalisation process rather than reported by the company. Part of the company's own Scope 3 was filed without a category, so it has no cell of its own. A cell marked “ESTIMATED” is a figure the company did not disclose, modelled by Mycelium.

Verification

Independent third parties involved in checking or preparing Recipharm AB's emissions data.

Independent assurance

Independently assured(limited assurance)by KPMG ABfor 2025

Carbon accountant

Position Greenprepared the 2025 figures

Climate targets

Science Based Targets initiative

Near-term target

Targets set (1.5°C), target year 2030

Source: Science Based Targets initiative, Companies Taking Action.

Contact Info

Country

Sweden

Browse carbon emissions data by industry

How scoring works

How the Mycelium Score is calculated

The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs peers in the same NACE section (emissions normalised against revenue, log-scaled between the 5th and 95th percentile of each company's latest reporting year in that section; a section needs at least 5 companies to be benchmarked). The band above 6.5 is earned through verified data quality on a claimed profile: declaring every reporting category yourself (up to 2.0), preparation by a carbon accountant (2.0) and independently audited figures (2.0). The total is multiplied by the transparency score and capped at 10. A disclosure with an implausibly large figure (Scope 1 or 2 over 300 million tonnes, a Scope 3 figure over 2 billion tonnes or a total over 2.5 billion tonnes) is not scored until it has been checked.

A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. Recipharm AB's score sits at the top of this page and in the score panel. Without a revenue figure to measure carbon intensity, or an industry classification to compare it within, a company has no score.

How the Transparency Score is calculated

The Transparency Score is the share of a company's estimated footprint that it reported itself, graded from A (very high) down to F (very low). Where a category is missing, Mycelium models what it would hold for a company of that size and industry and counts it as undisclosed, so an unreported category where the bulk of emissions sit hurts far more than a minor one. Unreported downstream categories (9 to 15) count at a quarter of their modelled size in this share; the carbon intensity behind the score still counts them in full. A Scope 3 total filed without a category breakdown earns very little credit for the part left unattributed, because it does not show which categories are inside it: a company can count business travel, leave purchased goods out entirely, and the total looks the same. Without a revenue figure the footprint cannot be modelled, so the company has no Transparency Score.

For Recipharm AB, the single biggest gap is Fuel & energy related activities (Scope 3 Category 3). Mycelium estimates it accounts for around 7% of the company's estimated footprint, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.

Other material categories Recipharm AB hasn't disclosed:

  • Franchises (Scope 3 Category 14), around 3% of the estimated footprint
  • Capital goods (Scope 3 Category 2), around 3% of the estimated footprint

In total, roughly 27% of Recipharm AB's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.

Cover of Mycelium's scoring methodology white paperRead the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)

Compare Recipharm AB with similar companies

Recipharm AB carbon emissions FAQs

What are Recipharm AB's carbon emissions?

In its 2025 reporting year, Recipharm AB disclosed total emissions of 196,109 tCO2e across all scopes. Including Mycelium estimates for undisclosed categories, the adjusted total is 206,764 tCO2e. Scope 3 accounted for the largest share of the reported total, around 89%.

Does Recipharm AB report Scope 1, Scope 2 and Scope 3 emissions?

For 2025, Recipharm AB's available disclosure covers Scope 1 (20,956 tCO2e), Scope 2 (805 tCO2e) and Scope 3 across 2 of the 15 GHG Protocol categories. Figures not reported by the company are shown as modelled estimates and labelled as such.

How transparent is Recipharm AB's emissions reporting?

Recipharm AB has a Mycelium transparency score of 79.2 out of 100. The score is the share of the company's estimated footprint that it reported itself, so an undisclosed category where most of its emissions sit weighs far more than a minor one.

Is Recipharm AB sustainable?

Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. Recipharm AB has a Mycelium Score of 4.9 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures, disclosure documents and climate targets on this page give the fuller picture.

Is Recipharm AB environmentally friendly?

Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. Recipharm AB disclosed 196,109 tCO2e for 2025, and its Mycelium Score of 4.9 out of 10 shows how that performance compares with similar companies in its sector.

Learn more about our methodology and where this data comes from.